Cilazapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure.[1][2]
Names | |
---|---|
Preferred IUPAC name
(1S,9S)-9-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid | |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.168.764 |
| |
KEGG |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H31N3O5 | |
Molar mass | 417.506 g·mol−1 |
log P | 2.212 |
Acidity (pKa) | 2.285 |
Basicity (pKb) | 11.712 |
Pharmacology | |
C09AA08 (WHO) | |
Oral | |
Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|
It was patented in 1982 and approved for medical use in 1990.[3]
Of the eight possible stereoisomers, only the all-(S)-form is medically viable.[citation needed]
It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.[4]